Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17237441 | 0.87 | GAA (0.47) | GAAMAPTPKMNAPRTLMNA | |
| SCHEMBL1034880 | 0.80 | NAPRT (0.63) | MAPTNAPRTLMNAKMT2ADHODH | |
| SCHEMBL31098672 | 0.78 | GAA (0.52) | GAAMAPTPKMNAPRTLMNA | |
| SCHEMBL13335724 | 0.77 | NAPRT (0.59) | MAPTNAPRTLMNAKMT2ADHODH | |
| SCHEMBL30370193 | 0.76 | POLB (0.76) | GAAMAPTPKMLMNAKMT2A | |
| SCHEMBL18160423 | 0.75 | GAA (0.50) | GAAMAPTPKMKMT2AGPBAR1 | |
| SCHEMBL10972794 | 0.75 | ALDH1A1 (0.47) | GAAKMT2AGPBAR1METPOLB | |
| SCHEMBL11238903 | 0.75 | MET (0.45) | GAAMAPTPKMKMT2AGPBAR1 | |
| SCHEMBL1036048 | 0.74 | NAPRT (0.56) | MAPTNAPRTLMNAKMT2ADHODH | |
| SCHEMBL781008 | 0.74 | NAPRT (0.56) | MAPTNAPRTLMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| CN-101321751-A | Met kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-12-10 | — | — | CN | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | GAA 3445/4885MAPT 3276/4885PKM 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.